Pfizer (PFE) Shares Bought by Weybosset Research & Management LLC

Weybosset Research & Management LLC boosted its position in shares of Pfizer (NYSE:PFE) by 13.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 12,847 shares of the biopharmaceutical company’s stock after purchasing an additional 1,500 shares during the quarter. Weybosset Research & Management LLC’s holdings in Pfizer were worth $465,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Peregrine Asset Advisers Inc. boosted its position in Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC boosted its position in Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 50 shares in the last quarter. Stone House Investment Management LLC boosted its position in Pfizer by 1.0% during the second quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 72 shares in the last quarter. Highland Private Wealth Management boosted its position in Pfizer by 0.8% during the second quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 76 shares in the last quarter. Finally, Autus Asset Management LLC boosted its position in Pfizer by 1.2% during the second quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 78 shares in the last quarter. Institutional investors own 71.19% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several brokerages have recently issued reports on PFE. Citigroup restated a “sell” rating on shares of Pfizer in a research report on Thursday, April 12th. Berenberg Bank restated a “neutral” rating and issued a $37.00 price objective on shares of Pfizer in a research report on Wednesday, April 11th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Thursday, April 12th. Jefferies Group set a $38.00 price objective on Pfizer and gave the company a “hold” rating in a research report on Friday, April 13th. Finally, UBS set a $42.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company. Pfizer presently has an average rating of “Hold” and a consensus target price of $39.20.

Pfizer stock opened at $36.63 on Monday. The firm has a market capitalization of $218,053.45, a P/E ratio of 13.82, a price-to-earnings-growth ratio of 1.83 and a beta of 0.90. Pfizer has a 52 week low of $31.67 and a 52 week high of $39.43. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 earnings per share. research analysts predict that Pfizer will post 2.96 EPS for the current year.

In other Pfizer news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now directly owns 36,959 shares in the company, valued at $1,374,505.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Charles H. Hill sold 42,393 shares of the company’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total value of $1,515,973.68. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock valued at $9,064,785 over the last quarter. Insiders own 0.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/23/pfizer-pfe-shares-bought-by-weybosset-research-management-llc.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply